Agalsidase beta Completed Phase 2 Trials for Fabry's Disease

IndicationsStatusPurposePhase
CompletedNot Available2
clinicaltrials.gov IdentifierTitleDrugs
NCT01304277This Study is Designed to Evaluate PD/PK and Safety of Replagal Manufactured by Two Different Processes.